- Home
- MDCX vs RLAY Comparison
MDCX vs RLAY Comparison
Compare MDCX & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | RLAY |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | 12 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MDCX | RLAY |
|---|---|---|
| Price | $0.46 | $12.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $23.50 | $16.86 |
| AVG Volume (30 Days) | ★ 8.4M | 2.6M |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $324.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $0.37 | $1.78 |
| 52 Week High | $8.90 | $13.04 |
Technical Indicators
Market Signals| Indicator | MDCX | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 34.89 | 72.30 |
| Support Level | $0.37 | $9.16 |
| Resistance Level | $1.70 | N/A |
| Average True Range (ATR) | 0.05 | 0.73 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 36.57 | 86.75 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).